多发性骨髓瘤不同疾病阶段骨髓内残留正常浆细胞的临床意义
研究基于NICHE队列(NCT04645199)1363例骨髓瘤患者,全面探讨残留正常浆细胞(NPCs)在整个疾病过程中的临床意义。结果显示,基线NPCs比例高(≥5%)者呈惰性特征,诊断或复发时高残留NPCs比例与良好生存独立相关,MRD阴性时高NPCs绝对百分比与更优临床获益及免疫重建相关。
要点
- 基线NPCs比例≥5%的骨髓瘤患者表现为低肿瘤负荷、血细胞减少少、免疫麻痹少及高危细胞遗传学少。
- 诊断或复发时高残留NPCs比例与良好生存独立相关。
- MRD阳性阶段按NPCs比例(<50%、50-90%、≥90%)分组,风险分层优于残留肿瘤对数水平。
核心结论
- 残留NPCs不仅是风险分层的有价值补充生物标志物,还为MRD的重分类和动力学提供了重要见解。
研究设计与样本
- 研究为基于NICHE队列(NCT04645199)的全面队列研究,纳入1363例骨髓瘤患者,探讨残留NPCs在整个疾病过程中的临床意义。
主要发现
- 基线NPCs比例高(≥5%)的患者表现为惰性特征,包括较低肿瘤负荷、较少血细胞减少、较少免疫麻痹和较少高危细胞遗传学。
- 诊断或复发时高残留NPCs比例与良好生存独立相关。
- MRD不可检测时高NPCs绝对百分比与更优临床获益和免疫重建相关。
- MRD阳性阶段,按NPCs比例(<50%、50-90%、≥90%)分组风险分层优于残留肿瘤对数水平。
- 基于时间依赖性NPCs比例趋势开发的动态MRD模型将患者分为三组,具有不同纵向趋势和不同预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Residual normal plasma cells (NPCs), which compete with tumor plasma cells, play an important role in multiple myeloma. However, large-scale cohort studies investigating residual NPCs, especially at the minimal residual disease (MRD) phase, are currently lacking. In this study, we conducted a comprehensive investigation into the clinical significance of residual NPCs throughout the entire disease course in 1363 myeloma patients from the NICHE cohort (NCT04645199). Our results revealed that myeloma patients with high baseline NPCs ratio (≥5%) exhibited distinct indolent features, characterized by lower tumor burden, reduced frequencies of cytopenia, immunoparesis, and high-risk cytogenetics. Importantly, high residual NPCs ratio at diagnosis or relapse was independently associated with favorable survival. High absolute percentages of NPCs at undetectable MRD were related with superior clinical benefit and immune reconstitution. At MRD-positive phases, grouping based on NPCs ratio (<50%, 50-90%, ≥90%) demonstrated better risk stratification compared to residual tumor log levels. Based on the time-dependent NPCs ratio trend, we developed a dynamic MRD model that classifies patients into three groups with diverse longitudinal trends, leading to distinct prognoses. Collectively, residual NPCs serves not only as a valuable complementary biomarker for risk stratification but also provides valuable insights on reclassifications and kinetics of MRD.
引用
- Yan W, Shi L, Xu J, et al. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma. Leukemia. 2024. PMID: 39095502. doi:10.1038/s41375-024-02366-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。